Leverone Jason A. sold $1K of OKUR
Leverone Jason A. (Chief Financial Officer) sold 303 shares of OnKure Therapeutics, Inc. (OKUR) at $4.40 on 2026-06-22.
How this was made
The 30-second read
Why it matters
Insider selling can modestly affect sentiment, but this filing alone does not provide new operational, financial, or regulatory information.
Market read
Traders may note the disclosed insider sale, but the text lacks any fundamental catalyst to drive repricing.
What to watch
No context on total holdings, prior sales cadence, or whether other insiders sold; absence of a 10b5-1 plan may increase scrutiny but doesn’t establish intent.
Background
The article is an SEC Form 4 insider transaction disclosure for OnKure Therapeutics, Inc.
Ticker impact
OnKure Therapeutics CFO Leverone sold 303 shares at $4.3963/share in an SEC Form 4 disclosed June 24.
Likely minimal near-term impact; any effect would be sentiment-only and short-lived.
The filing is a small, disclosed insider sale with no 10b5-1 plan and no accompanying fundamental catalyst in the text.
Market effects
No sector read-across provided; this is company-specific insider activity only.
None indicated.
None indicated.
Counterpoint
The sale could be routine liquidity management rather than a bearish signal, especially given the small share count.
Key entities
- issuerOnKure Therapeutics, Inc.
Subject of the Form 4 insider transaction; CFO Leverone sold shares on June 22, filed June 24.
- insiderLeverone Jason A.
Chief Financial Officer who executed the open-market sale of 303 shares.